PipelinePharma Logo
PipelinePharma Logo

CTD Dossier Marketplace

Direct connection with CTD dossier (IP) owners and manufacturers

Marketing Authorizations Database

Search across marketing authorization registers
Sign in Get started

Generics Products found!

Innovative

Biosimilars

Medical devices

Nutraceuticals

Filters

Carbidopa manufacturers

Filters

Filters

Filters , active

Country of origin : India
None products found

carbidopa + levodopa

Tablets, immediate release (IR) 10/100mg, 12.5/50mg, 25/100mg, 25/250mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
Canada, United Kingdom, TGA
Registered in
Czech Republic , Germany , Denmark , Spain , Finland , Ireland , Malta , Netherlands , Norway , Portugal , United States , Canada
Manufacturer #10765
A pharmaceutical manufacturer providing end-to-end development and commercial manufacturing of pharmaceutical products, with large-scale capacity for oral solid dosage forms such as tablets, capsules and sachets, supported by dedicated analytical labs and validated quality systems. The company states its manufacturing is designed to conform to EU and FDA cGMP requirements and lists substantial annual output capacity for key dosage forms, positioning it as a reliable supply partner for regulated and semi-regulated markets. Quality information on the site confirms multiple GMP approvals, including EU-GMP certification and GMP certifications from TGA (Australia), MHRA (UK), Ukraine’s health authority, and WHO-GMP compliance, all referenced in its regulatory and certification materials.

Manufacturer usually replies in 64 days

levodopa + carbidopa

Tablets 250 mg + 25 mg, 50 mg + 200 mg, 25 mg + 100 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, FDA
Manufacturer #2655

The company is a pharmaceutical manufacturer engaged in the research, development, production and distribution of a broad portfolio of branded and generic pharmaceutical products across multiple therapeutic areas, operating with state-of-the-art manufacturing facilities and quality systems to produce and supply these pharmaceutical products to healthcare providers and markets in India and internationally.

Manufacturer usually replies in 17 days

levodopa + carbidopa + entacapone

Tablets 50 mg + 12.5 mg + 200 mg , 75 mg + 18.75 mg + 200 mg , 100 mg + 25 mg + 200 mg, 125 mg + 31.25 mg + 200 mg, 150 mg + 37.5 mg + 200 mg , 200 mg + 50 mg + 200 mg , 175 mg + 43.75 mg + 200 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
El Salvador , Guatemala , Honduras , Nicaragua
Comments
Reference product: Stalevo ®DCP status: Completed
Manufacturer #15189
The company, which was founded in 1989, is involved in developing, manufacturing, and distributing a wide range of formulations for anti-infectives, cardiovascular, anti-diabetic, dermatological, and hormone treatment. The corporation has a global presence in 170 + countries, 60+ WHO-prequalified medications, and 3700+ product registrations.

Manufacturer usually replies in 29 days

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Carbidopa

Carbidopa is a drug used in the treatment of Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant because allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect, thus paving way for the best possible absorption. Parkinson’s disease damages the neurons that produce dopamine, the motor symptoms of PD appear, including tremor, rigidity, impaired balance, and includes loss of spontaneous movement. These are motor symptoms of PD related to depletion of the neurotransmitter (chemical messenger) dopamine in the brain. Carbidopa prevents the conversion of L-DOPA to dopamine peripherally, thus reducing the side effects caused by dopamine on the periphery, and finally increasing the concentration of L-DOPA and dopamine in the brain.
Many combinations of Carbidopa/levodopa carry the brand names of Kinson, Sinemet, Pharmacopa and Atamet.
Amerigens Pharmaceuticals Ltd, first approved product by the FDA containing only carbidopa in 2014. Initially, The combination treatment of carbidopa/levodopa was originally developed by Watson Labs, However, the historical information by the FDA brings back to the approval of this combination therapy by Mayne Pharma in 1992.

Forms and dosage

The combination of levodopa/carbidopa is sold as a regular tablet, an orally disintegrating tablet, an extended-release, long-acting tablet, and an extended-release, long-acting capsule to take by mouth. It is also sold as a suspension to be given into your stomach through a PEG-J tube or sometimes through a naso-jejunal tube using a special infusion pump.
The regular and orally disintegrating tablets are given three or four times a day and extended-
release capsule is usually taken three to five times a day. The suspension is usually given as a morning dose by infusion over 10 to 30 minutes and then as a continuous dose given by infusion over 16 hours.

The cost of Carbidopa

In the USA, the consumers have to pay an average retail price of $44.23 and in the UK a supply of 100 tablets of 25mg strength cost 35 pounds. In India, the same supply costs less than dollar for a generic brand.

How does it work?

Carbidopa works by inhibiting aromatic-L-amino-acid decarboxylase, an enzyme important in the biosynthesis of L-tryptophan to serotonin and in the biosynthesis of L-DOPA to dopamine (DA). Increased dopamine availability increases the effectiveness of the remaining neurons thus providing alleviation from symptoms for a time. However, exogenously provided, L-DOPA gets metabolized peripherally before reaching the blood–brain barrier. But, Carbidopa decreases peripheral DDC conversion of L-DOPA before it crosses the blood–brain barrier. Carbidopa acts as a peripheral DDC inhibitor, it has no effect on brain DDC conversion of L-DOPA to dopamine. As result of these actions, a greater proportion of the exogenously provided levodopa/L-DOPA reaches the brain

Finding Carbidopa Manufacturers and Suppliers

 
For sourcing Carbidopa, manufacturers and sellers, log onto Pipelinepharma’s B2B online market place. It is a sophisticated B2B marketplace platform which is powered by our intuitive interface, which helps you narrow down and compare options for you to make the best decision.
 
Pipelinepharma’s B2B online market place has a host of manufacturers and suppliers, making it the ideal sourcing platform. You can choose from the wide list of manufacturers and suppliers suitable for your specific sourcing and pricing needs.

Popular Searches

Amoxicillin manufacturers Atorvastatin manufacturers Benzocaine manufacturers Calcium carbonate manufacturers Cloperastine fendizoate manufacturers Gabapentin manufacturers Hyaluronic acid manufacturers Ibuprofen manufacturers Ivermectin manufacturers Levothyroxine manufacturers Lisinopril manufacturers Losartan manufacturers Magnesium manufacturers Melatonin manufacturers Metformin manufacturers Methotrexate manufacturers Metoprolol manufacturers Omeprazole manufacturers Paracetamol manufacturers Prednisone manufacturers Pregabalin manufacturers Semaglutide manufacturers Testosterone enanthate manufacturers Vitamin B12 manufacturers

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.